Analysts Offer Insights on Healthcare Companies: Sunesis Pharma (SNSS) and Syndax Pharmaceuticals Inc (SNDX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sunesis Pharma (SNSS) and Syndax Pharmaceuticals Inc (SNDX) with bullish sentiments.

Sunesis Pharma (SNSS)

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Sunesis Pharma today and set a price target of $6. The company’s shares opened today at $0.67, close to its 52-week low of $0.20.

Singh wrote:

“Sunesis (SNSS) reported 4Q18 and gave a corporate update on 3/7. Auspiciously, the update came after a positive update by reversible BTK inhibitor developer peer ARQL (rated OP), which underscored the potential opportunity for non-covalently bound BTK-inhibition. SNSS’ update encouragingly framed the clinical objectives for 2019, which center around a key clinical update at the European Hematology Association (EHA) meeting on June 13-16. With the company enrolling up to 6 evaluable patients at the first therapeutic dose level of 100mg BID, we anticipate the June update will have thoughtful clinical depth and clarity. Keeping an eye on safety, we stay bullish on the name.”

According to TipRanks.com, Singh is a 3-star analyst with an average return of 1.4% and a 43.1% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Sunesis Pharma with a $0.50 average price target.

See today’s analyst top recommended stocks >>

Syndax Pharmaceuticals Inc (SNDX)

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Syndax Pharmaceuticals Inc yesterday. The company’s shares opened today at $5.25, close to its 52-week low of $3.39.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 1.7% and a 43.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Nektar Therapeutics, and United Therapeutics.

Syndax Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.60, representing a 292.4% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $16 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts